Bernstein lowered the firm’s price target on Vertex Pharmaceuticals (VRTX) to $572 from $577 and keeps an Outperform rating on the shares. The firm notes revenue was in line while EPS beat by 5% due to cost discipline. Shares have pulled back 14% since the pove Phase 3 jump due to concerns about upcoming competitor cystic fibrosis data from Sionna Therapeutics (SION). Bernstein is not overly concerned about Sionna Therapeutics, and remains bullish into AMKD data expected early 2027.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRTX:
- Vertex Pharmaceuticals Earnings Call Highlights New Growth Engines
- Closing Bell Movers: Pinterest jumps 15% on earnings beat; Palantir slips
- Moderna updates on Cystic Fibrosis collaboration with Vertex Pharmaceuticals
- Vertex Pharmaceuticals reports Q1 EPS $4.02, consensus $4.31
- Vertex Pharmaceuticals affirms FY26 revenue $12.95B-$13.1B, consensus $13.05B